FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
FDA General

FDA, MHRA Launch Liaison Program for Regulatory Cooperation

FDA and the UK's Medicines and Healthcare products Regulatory Agency announce a new liaison program designed to strengthen collaboration between the t...

latest-news-card-1
Human Drugs

Jazz Trial Misses Survival Endpoint for Zepzelca in Lung Cancer

Jazz Pharmaceuticals says its Phase 3 LAGOON study evaluating Zepzelca (lurbinectedin) in relapsed small cell lung cancer failed to meet its primary e...

latest-news-card-1
Human Drugs

AstraZeneca's Truqap for Prostate Cancer Approved

FDA approves AstraZeneca's AKT inhibitor Truqap (capivasertib) in combination with abiraterone and prednisone for adults with PTEN-deficient metastati...

latest-news-card-1
Human Drugs

Draft Guidance Clarifies Orange Book Patent Submission Forms

FDA posts a draft guidance to assist NDA sponsors in properly submitting patent information for listing in the agency's Orange Book.

latest-news-card-1
Human Drugs

Welireg-Keytruda Combo OKd as Adjuvant Kidney Cancer Therapy

FDA approves Merck's Welireg (belzutifan) in combination with Keytruda (pembrolizumab) as an adjuvant treatment for certain patients with renal cell c...

latest-news-card-1
Human Drugs

Amgen Outlines Basis for Hearing in Tavneos Withdrawal Effort

A just-posted notice from Amgen outlines the basis for the company's defense of why its ANCA-associated vasculitis drug Tavneos should not be withdraw...

latest-news-card-1
FDA General

17 Senate Democrats Hit HHS on FDA, Other Changes

Some 17 Senate Democrats write to HHS secretary Robert F. Kennedy Jr., questioning many of his personnel decisions and expressing concern about the na...

latest-news-card-1
Human Drugs

Zasocitinib Beats Sotyktu in Head-to-Head Study: Takeda

Takeda says its investigational TYK2 inhibitor zasocitinib performed significantly better than Bristol Myers Squibbs Sotyktu in a Phase 3 head-to-head...

latest-news-card-1
Human Drugs

CGMP Violations Seen in Port Jervis Records Review

FDA cautions Port Jervis Laboratories in Port Jervis, NY, about CGMP violations in its manufacturing of over-the-counter drugs.

latest-news-card-1
Medical Devices

Risk Management an Ever-Evolving Responsibility: Thomas

CDRH associate director for compliance and quality Keisha Thomas tells the RAPS Quality Conference about FDAs new Quality Management System Regulation...